About Lightchain Capital
Lightchain Capital is a venture capital firm founded in 2018. It is primarily based out of St. Louis, United States. As of Jul 2026, Lightchain Capital is an active investor, having invested in 12 companies, with 2 new investments in the last 12 months. It primarily invests in Series C round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series C round of Allotera Therapeutics Overall, Lightchain Capital portfolio has seen 1 IPO, namely C4 Therapeutics. A lot of funds co-invest with Lightchain Capital, with names like Cobro Ventures sharing a substantial percentage of its portfolio. Lightchain Capital has team of 3 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 2 more
Portfolio IPOs
Portfolio Soonicorns
Deals in last 12 months
Lightchain Capital's List of Top Investments
Lightchain Capital has a portfolio of 12 companies. Their most notable investments are in Mana Therapeutics and NextRNA.Their portfolio spans across and United States. They have invested in Life Sciences, High Tech, Enterprise Applications and 3 other sectors, across stages such as Series A, Series B and 2 more. Here is the list of top investments by Lightchain Capital:Developer of small molecule drugs for treating cancer. Its Degronimid platform incorporates highly selective small-molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural proteasome system. It has developed CFT7455 for treating hematologic malignancies, CFT8634 for sarcoma, BRAF V600E for slid tumors.
Key facts about C4 Therapeutics
- Founded Year: 2016
- Location: Cambridge (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $223M
- Employee Count: 114 as on Jun 30, 2026
- Investors: HTIF, Bain Capital Life Sciences and 27 Others
- Latest Funding Round: Post IPO, Jan 04, 2024, $*****
- Highlight: Public
2. Geneoscopy
Developer of non-invasive biomarker tests for colorectal cancer. The flagship assay analyzes stool samples for a panel of disease-associated mRNA biomarkers using a proprietary diagnostic algorithm to detect colorectal cancer. The company plans that its assay will be used to screen patients in need of a more invasive colonoscopy.
Key facts about Geneoscopy
- Founded Year: 2015
- Location: St. Louis (United States)
- Stage: Series C
- Total Funding till date: $219M
- Employee Count: 71 as on Jun 30, 2026
- Investors: Innovatus Capital Partners, PavLyfe and 18 Others
- Latest Funding Round: Series C, Jan 08, 2025, $*****
- Highlight: Editors' Pick
Provider of diagnostic and therapeutic products for oncology. It offers a non-invasive diagnostics focus on multiple myeloma and evaluate patients’ immune system cells to determine the patient responding to immunotherapies.
Key facts about Predicta Biosciences
- Founded Year: 2023
- Location: Boston (United States)
- Stage: Series A
- Total Funding till date: $28.6M
- Employee Count: 21 as on Jun 30, 2026
- Investors: Illumina Ventures, Engine Ventures and 7 Others
- Latest Funding Round: Series A, Oct 01, 2025, $*****
- Highlight: Editors' Pick
4. Wugen
Developer of CAR-T cell therapy for treating T-cell malignancies. The company has developed an allogeneic CAR-T therapy platform for the treatment. Deletion of the T-cell receptor (TCR) enables the use of T-cells from healthy donors without the risk of life-threatening Graft vs. Host Disease (GvHD). It has developed a pipeline for Head & Neck Cancer, Melanoma, and Solid Tumors.
Key facts about Wugen
- Founded Year: 2018
- Location: St. Louis (United States)
- Stage: Series C
- Total Funding till date: $251M
- Employee Count: 51 as on Jun 30, 2026
- Investors: Aisling Capital, Tybourne Capital Management and 11 Others
- Latest Funding Round: Series C, Aug 22, 2025, $*****
- Highlight: Editors' Pick
5. AI Proteins
Developer of de novo designed miniproteins for therapeutic applications. The company engineers proteins from scratch, controlling function, selectivity, stability, and pharmacology. This allows for the creation of multivalent and multispecific constructs. The designed proteins are intended to minimize off-target effects, drug interactions, and unwanted immune responses. The company aims to deliver biologics that are potent, programmable, and safe.
Key facts about AI Proteins
- Founded Year: 2021
- Location: Boston (United States)
- Stage: Series A
- Total Funding till date: $59.7M
- Employee Count: 41 as on Jun 30, 2026
- Investors: Mission BioCapital, Intel Ignite and 3 Others
- Latest Funding Round: Series A, Nov 20, 2025, $*****
- Highlight: Editors' Pick
Lightchain Capital's Year-on-Year Investment Trends
Lightchain Capital has invested in 12 companies over the last 7 years, with an average of 1 new investment annually in the last 5 years. In 2025, it made 5 investments, while as of Jul 2026, it has made 1 investment in this year. Its most recent first time investment was in Predicta Biosciences and most recent follow-on round was in Allotera Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 1 | 1 |
2025 | 2 | 3 | 5 |
2024 | 0 | 0 | 0 |
2023 | 1 | 0 | 1 |
2022 | 2 | 0 | 2 |
2021 | 2 | 1 | 3 |
2020 | 1 | 0 | 1 |
2019 | 2 | 0 | 2 |
Lightchain Capital's Investments by Stage
Lightchain Capital has made 4 investments in Series A stage with an average round size of $28.3M, 3 investments in Series B stage with an average round size of $99.5M, 2 investments in Series C stage with an average round size of $73.2M and 1 investment in Seed stage with an average round size of $18.2M.Stage of entry | No. of Investments |
|---|---|
Series A | 4 |
Series B | 3 |
Series C | 2 |
Seed | 1 |
Note: We have considered here, only first round of investments
Lightchain Capital's Investments by Sector
Lightchain Capital has a diverse portfolio, with companies operating in the Life Sciences, Business Services, Enterprise Applications, HealthTech and High Tech. Notably, it has invested in 10 Enterprise (B2B) companies, 9 Tech companies, 1 Consumer (B2C) company and at least 1 company focusing on Social impact.Sector | No. of Investments |
|---|---|
Life Sciences | 9 |
Business Services | 1 |
Enterprise Applications | 1 |
HealthTech | 1 |
High Tech | 1 |
Note: We have considered here, only first round of investments
Lightchain Capital's Investments by Geography
Lightchain Capital has made most investments in United States (10).Lightchain Capital's recent investments
Lightchain Capital has made 1 investments in 2026 so far - Allotera Therapeutics.Here are the most recent investments by Lightchain Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jul 09, 2026 | United States | Series C | 4696 | ||
Nov 20, 2025 | United States | Series A | 1245 | [+2] | |
Oct 01, 2025 | United States | Series A | 1228 | [+5] | |
Aug 22, 2025 | United States | Series C | 7381 | [+6] | |
Aug 22, 2025 | United States | Series C | 4041 | [+1] |
IPOs and Publicly Listed companies in Lightchain Capital's Portfolio
1 of Lightchain Capital's portfolio company became public - C4 Therapeutics. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2020 at marketcap of $789MHere are Lightchain Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 02, 2020 | Jun 16, 2020 | Series B | 5615 |
Team profile of Lightchain Capital
Lightchain Capital has a team of 3 members including 2 Partners and 1 Principal located in United States. Lightchain Capital's team does not sit on the board of any company as of now.Here is a list of all team members in Lightchain Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | - | - | - | |
Partner | St. Louis | - | ||
Principal | St. Louis | - |
Co-investors of Lightchain Capital
Over the past 7 years, 88 investors have co-invested in Lightchain Capital's portfolio companies. This includes only funds.
- Invested before Lightchain Capital: Roche, BioGenerator and 17 others have invested in rounds before Lightchain Capital. There are 2 companies where Roche has invested before Lightchain Capital and 2 companies where BioGenerator has invested before Lightchain Capital.
- Top Co-investors of Lightchain Capital: 43 investors entered a company along with Lightchain Capital. These include investors like Cobro Ventures (3 companies).
- Invested after Lightchain Capital: A total of 26 investors have invested in Lightchain Capital's portfolio after their investments. Top Investors include Betta Pharmaceuticals (1 company), LightChain Capital (1 company) and LabCorp (1 company).
Recent News related to Lightchain Capital
•
•
AI Proteins Raises $41.5M in Series A FinancingFinSMEs•Nov 20, 2025•Lightchain Capital, Sante, Mission BioCapital, Cobro Ventures
•
Predicta Biosciences Raises $23.4M in Series A FundingFinSMEs•Oct 02, 2025•BrightEdge, Predicta Biosciences, Mass General Brigham, Engine Ventures and 5 others
•
Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Testsintelligence360•Jan 16, 2025•Geneoscopy, Bio Rad, LabCorp, Morningside and 4 others
•
•
Biotechnology company AI Proteins raises USD 18.2 million in Seed fundingVcbay News•Nov 05, 2022•Lightchain Capital, AI Proteins
•
•
NextRNA Launches with $56 Million in Funding to Bring Transformative Non-Coding RNA-Directed Medicines to PatientsBusiness Wire•Mar 01, 2022•NextRNA, Cobro Ventures, Lightchain Capital, Circle Squared and 4 others
